ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 59 filers reported holding ASCENDIS PHARMA A/S in Q3 2017. The put-call ratio across all filers is - and the average weighting 1.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2020 | $8,208,000 | +15.3% | 55,500 | -12.2% | 2.37% | -31.3% |
| Q1 2020 | $7,117,000 | +127.4% | 63,200 | +180.9% | 3.45% | +345.2% |
| Q4 2019 | $3,130,000 | -38.2% | 22,500 | -68.5% | 0.78% | -57.1% |
| Q3 2018 | $5,066,000 | -75.5% | 71,500 | -77.0% | 1.81% | -51.0% |
| Q2 2018 | $20,695,000 | -41.8% | 311,111 | -42.8% | 3.68% | -36.6% |
| Q1 2018 | $35,578,000 | +67.3% | 544,000 | +2.4% | 5.81% | +44.7% |
| Q4 2017 | $21,272,000 | +17.4% | 531,000 | +6.2% | 4.02% | +23.6% |
| Q3 2017 | $18,125,000 | -29.4% | 500,000 | -45.9% | 3.25% | -54.8% |
| Q2 2017 | $25,664,000 | +66.6% | 924,483 | +68.1% | 7.18% | +96.7% |
| Q1 2017 | $15,400,000 | +32.3% | 550,000 | -4.4% | 3.65% | -15.7% |
| Q4 2016 | $11,644,000 | +59.6% | 575,309 | +58.5% | 4.33% | +58.1% |
| Q3 2016 | $7,296,000 | +16.3% | 363,000 | -23.2% | 2.74% | -9.2% |
| Q2 2016 | $6,274,000 | -45.8% | 472,800 | -24.2% | 3.02% | -53.4% |
| Q1 2016 | $11,568,000 | +21.6% | 623,631 | +20.1% | 6.47% | +42.2% |
| Q4 2015 | $9,513,000 | +14.4% | 519,243 | +10.5% | 4.55% | -5.5% |
| Q3 2015 | $8,317,000 | +11.5% | 469,893 | +11.4% | 4.82% | +4.4% |
| Q2 2015 | $7,458,000 | +88.0% | 421,851 | +84.5% | 4.61% | +38.1% |
| Q1 2015 | $3,966,000 | – | 228,612 | – | 3.34% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 1,797,745 | $265,886,000 | 19.06% |
| RA Capital Management | 4,914,955 | $726,922,000 | 14.16% |
| Sofinnova Investments, Inc. | 1,109,874 | $164,150,000 | 10.35% |
| Eventide Asset Management | 1,709,848 | $252,887,000 | 5.50% |
| Asymmetry Capital Management, L.P. | 47,599 | $7,040,000 | 5.39% |
| BERYLSON CAPITAL PARTNERS, LLC | 58,200 | $8,608,000 | 5.30% |
| Avoro Capital Advisors LLC | 1,750,000 | $258,825,000 | 5.12% |
| Eversept Partners, LP | 220,344 | $32,588,878 | 4.47% |
| Spyglass Capital Management LLC | 452,104 | $66,866,000 | 4.14% |
| Orbimed Advisors | 1,562,986 | $231,166,000 | 3.25% |